Quantitative and qualitative characterization of Two PD-L1 clones: SP263 and E1L3N

被引：0
|
作者：
Jacquelyn Smith
Mark D. Robida
Krista Acosta
Bharathi Vennapusa
Amita Mistry
Greg Martin
Alton Yates
H. James Hnatyszyn
机构：
[1] Ventana Medical Systems Inc.,Companion Diagnostics Pharma Services, Assay Development
[2] Roche Tissue Diagnostics,Companion Diagnostics Pharma Services, Pathology Office
[3] Ventana Medical Systems Inc.,Companion Diagnostics, Project Management Office
[4] Roche Tissue Diagnostics,Companion Diagnostics, Pharma Services, Clinical Services Management
[5] Ventana Medical Systems Inc.,Companion Diagnostics Pharma Services, CDx CAP/CLIA Lab Operations
[6] Roche Tissue Diagnostics,undefined
[7] Ventana Medical Systems Inc.,undefined
[8] Roche Tissue Diagnostics,undefined
[9] Ventana Medical Systems Inc.,undefined
[10] Roche Tissue Diagnostics,undefined
来源：
Diagnostic Pathology | / 11卷
关键词：
PD-L1; IHC; NSCLC; SP263; E1L3N;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [1] Quantitative and qualitative characterization of Two PD-L1 clones: SP263 and E1L3N
    Smith, Jacquelyn
    Robida, Mark D.
    Acosta, Krista
    Vennapusa, Bharathi
    Mistry, Amita
    Martin, Greg
    Yates, Alton
    Hnatyszyn, H. James
    DIAGNOSTIC PATHOLOGY, 2016, 11
  • [2] Interobserver concordance of PD-L1 clones SP263 and E1L3N in non-small cell lung carcinoma (NSCLC): two centre study
    Bozkurtlar, E.
    Karaman, D.
    Batur, S.
    VIRCHOWS ARCHIV, 2021, 479 (SUPPL 1) : S51 - S52
  • [3] Epitope mapping of PD-L1 primary antibodies (28-8, SP142, SP263 E1L3N).
    Schats, Kelly
    Van Vre, Emily A.
    Schrijvers, Darien
    De Meester, Ingrid
    Kockx, Mark
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [4] PD-L1 Expression in Metastatic Clear Cell Renal Cell Carcinoma Using Sp142, Sp263 and E1L3N
    Brunelli, Matteo
    Calio', Anna
    Munari, Enrico
    Pedron, Serena
    Ciocchetta, Elisa
    Bogina, Giuseppe
    Zamboni, Giuseppe
    Martignoni, Guido
    LABORATORY INVESTIGATION, 2020, 100 (SUPPL 1) : 862 - 862
  • [5] PD-L1 Expression in Metastatic Clear Cell Renal Cell Carcinoma Using Sp142, Sp263 and E1L3N
    Brunelli, Matteo
    Calio, Anna
    Munari, Enrico
    Pedron, Serena
    Ciocchetta, Elisa
    Bogina, Giuseppe
    Zamboni, Giuseppe
    Martignoni, Guido
    MODERN PATHOLOGY, 2020, 33 (SUPPL 2) : 862 - 862
  • [6] Comparison of E1L3N and SP263 clones of PD-L1 in non-small cell lung carcinoma (NSCLC): may it be associated with cut-off value?
    Karaman, D.
    Bozkurtlar, E.
    VIRCHOWS ARCHIV, 2021, 479 : S296 - S296
  • [7] An interobserver reproducibility study on PD-L1 (SP263) in urothelial carcinoma
    Barut, N. B.
    Hurdogan, O.
    Kilicaslan, I.
    Ozluk, Y.
    VIRCHOWS ARCHIV, 2024, 485 : S521 - S521
  • [8] PD-L1 expression and the prognostic significance in gastric cancer: a retrospective comparison of three PD-L1 antibody clones (SP142, 28–8 and E1L3N)
    Jing Ma
    Jianhui Li
    Meirui Qian
    Weili Han
    Miaomiao Tian
    Zengshan Li
    Zhe Wang
    Shuixiang He
    Kaichun Wu
    Diagnostic Pathology, 13
  • [9] Programmed cell death ligand-1 (PD-L1) expression in extrahepatic biliary tract cancers: a comparative study using 22C3, SP263 and E1L3N anti-PD-L1 antibodies
    Ahn, Soomin
    Lee, Yangkyu
    Kim, Ji-Won
    Lee, Jong-Chan
    Hwang, Jin-Hyeok
    Yoon, Yoo-Seok
    Cho, Jai Young
    Han, Ho-Seong
    Choi, YoungRok
    Kim, Haeryoung
    HISTOPATHOLOGY, 2019, 75 (04) : 526 - 536
  • [10] PD-L1 IHC validation and comparison of E1L3N & SP142 mAbs in melanoma
    Schats, K.
    van Vre, E.
    De Schepper, S.
    Neyns, B.
    De Meester, I.
    Kockx, M.
    ANNALS OF ONCOLOGY, 2015, 26 : 8 - 8
12345